Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer

Aurora kinase A (AURKA) regulates the cell cycle checkpoint and maintains genomic integrity. AURKA is overexpressed in various malignant tumors and its upregulation induces chromosomal instability, which leads to aneuploidy and cell transformation. To investigate the role of AURKA in endometrial cancer, we evaluated the association of immunohistochemical expression of AURKA with clinicopathological factors. Furthermore, we examined the effects of AURKA inhibition by transfected siRNA in HEC-1B cells on colony-forming ability, invasion and migration capacity, and chemosensitivity. Immunohistochemical staining showed that overexpression of AURKA was significantly associated with tumor grade (P<0.05) and poor histologic differentiation (P<0.05). The recurrence rate also tended to be high in cases with overexpression of AURKA (P<0.1) and these cases also had a tendency for shorter disease-free survival (DFS) (P<0.1). AURKA inhibition in endometrial cancer cell lines significantly decreased cell growth, invasion and migration (P<0.05), and increased chemosensitivity to paclitaxel. We also evaluated the efficacy of a combination of AURKA siRNA and paclitaxel against subcutaneous tumors formed in a nude mouse. After treatment, the tumor volume shrank significantly compared to treatment with paclitaxel only (P<0.05). To our knowledge, this is the first study in endometrial carcinoma to show a correlation between overexpression of AURKA and tumor grade, histological type and sensitivity to paclitaxel. AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis.

[1]  Anil K Sood,et al.  Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  H. Iwase,et al.  A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer , 2013, BMC Cancer.

[3]  V. Adamo,et al.  The role of Aurora-A inhibitors in cancer therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Kawai,et al.  Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis , 2005, Oncogene.

[5]  J. Cigudosa,et al.  Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. , 2003, Cancer research.

[6]  H. Friess,et al.  Overexpression of Oncogenic STK 15 / BTAK / Aurora A Kinase in Human Pancreatic Cancer 1 , 2003 .

[7]  G. Hannon,et al.  Suppression of p 160 ROCK bypasses cell cycle arrest after Aurora-A STK 15 depletion , 2004 .

[8]  Wenlin Huang,et al.  Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. , 2007, Cancer research.

[9]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[10]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[11]  Y. Li,et al.  Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp. , 2011, Molecular medicine reports.

[12]  S. Sen,et al.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.

[13]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[14]  T. Furukawa,et al.  AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer , 2006, Oncogene.

[15]  Chiao-Ying Lin,et al.  Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[16]  H. Friess,et al.  Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Saya,et al.  RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. , 2005, Cancer research.

[18]  S. Tsunoda,et al.  The Suppression of Aurora-A/STK15/BTAK Expression Enhances Chemosensitivity to Docetaxel in Human Esophageal Squamous Cell Carcinoma , 2007, Clinical Cancer Research.

[19]  D. Glover,et al.  Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles , 1995, Cell.

[20]  Naoshi Nishida,et al.  High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers , 2007, Cancer biology & therapy.

[21]  D. Aoki,et al.  Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. , 2013, Biomedical reports.

[22]  S. Fujita,et al.  Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[23]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[24]  G. Gopalan,et al.  Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. , 2007, Endocrine-Related Cancer.

[25]  G. Mills,et al.  Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2 , 2010, Clinical Cancer Research.

[26]  Fan Yang,et al.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma , 2011, Modern Pathology.

[27]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[28]  A. Godwin,et al.  Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion , 2014, Oncogene.

[29]  H. Kashima,et al.  Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. , 2005, Human pathology.

[30]  Jie Xu,et al.  Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. , 2008, Carcinogenesis.

[31]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[32]  M. Todaro,et al.  Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. , 2010, Cancer research.

[33]  G. Hortobagyi,et al.  STK15/Aurora‐A expression in primary breast tumors is correlated with nuclear grade but not with prognosis , 2004, Cancer.

[34]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[35]  A. Sood,et al.  Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients , 2007, Clinical Cancer Research.

[36]  Young-Sun Lin,et al.  Suppression of the STK15 oncogenic activity requires a transactivation‐independent p53 function , 2002, The EMBO journal.

[37]  M. Cazales,et al.  CDC25B Phosphorylation by Aurora A Occurs at the G2/M Transition and is Inhibited by DNA Damage , 2005, Cell cycle.

[38]  J. Inazawa,et al.  The Clinical Significance of Aurora-A/STK15/BTAK Expression in Human Esophageal Squamous Cell Carcinoma , 2005, Clinical Cancer Research.

[39]  S. Nicosia,et al.  Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215* , 2004, Journal of Biological Chemistry.

[40]  Y. Nakamura,et al.  Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation , 2001, British Journal of Cancer.

[41]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[42]  A. Walch,et al.  Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy , 2007, Clinical Cancer Research.

[43]  Y. Jan,et al.  Integrating Bioinformatics and Clinicopathological Research of Gastrointestinal Stromal Tumors: Identification of Aurora Kinase A as a Poor Risk Marker , 2012, Annals of Surgical Oncology.

[44]  G. Hannon,et al.  Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  X. Wang,et al.  Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells , 2012, Cancer Gene Therapy.

[46]  Huan Yang,et al.  Aurora‐A induces cell survival and chemoresistance by activation of Akt through a p53‐dependent manner in ovarian cancer cells , 2006, International journal of cancer.

[47]  D. Zheleva,et al.  Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells , 2012, British Journal of Cancer.

[48]  Henk M. W. Verheul,et al.  Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis , 2013, British Journal of Cancer.

[49]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[50]  Feng Jiang,et al.  Amplification/overexpression of a mitotic kinase gene in human bladder cancer. , 2002, Journal of the National Cancer Institute.